WINDLAS
NSEWindlas Biotech Limited (SMALL CAP)
Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹829.95
4.05 (0.49%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹1.75K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
25.6
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹697.4+19.0%
52W High₹1,097.9-24.4%
Current Price
₹829.95
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹663.96
Upper Circuit₹995.94
Reference Price
₹829.95
Investment Checklist
Head and Shoulders on 1D (BREAKOUT CONFIRMED) — target ₹716.1
Inverse Head and Shoulders on 1D (BREAKOUT CONFIRMED) — target ₹904.25
Volume divergence: Bullish (price down, volume up)
EMA(50) Crossover: Price crossed above EMA(50): Fresh bullish momentum signal.
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
80%
Trend
NEUTRAL
NEUTRAL
Mixed MA signals — sideways/transition
EMA20
840.77
EMA50
829.1
EMA200
846.1
Price Action
MIXED
NEUTRAL
Higher Highs2
Higher Lows5
Lower Highs7
Lower Lows3
Support & Resistance Levels
Resistance (Above)
₹842.32
₹852.55
₹875.00
₹884.90
₹900.44
Support (Below)
₹818.00
₹806.02
₹788.50
₹767.79
₹736.72
Volume Analysis
TrendSTABLE
Change+5.50%
Unusual VolumeNo
Divergence Detected
Bullish (price down, volume up)
Stop Loss Levels
Fixed Risk
1% Risk₹821.65
3% Risk₹805.05
5% Risk₹788.45
7% Risk (Custom)
₹771.85Technical Levels
1x ATR (Volatility)₹801.63
2x ATR (Swing)₹773.31
3x ATR (Trend)₹744.99
Immediate Support₹818.00
Moving Averages
EMA 50 (Trend)₹829.10
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹198 Cr | ₹210.1 Cr | ₹222.4 Cr | ₹233.1 Cr |
| Net Profit | ₹16.3 Cr | ₹17.7 Cr | ₹17.8 Cr | ₹15 Cr |
| EPS | — | ₹8.43 | ₹8.48 | ₹7.12 |
| Operating Profit | ₹30.5 Cr | ₹31.8 Cr | ₹32.2 Cr | ₹28.9 Cr |
ROE
12.06%
ROCE
15.63%
Debt/Equity
0.06
Current Ratio
2.11
OPM
12.42%
NPM
6.44%
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Windlas Biotech Limited | ₹829.95 | +0.49% | 25.7 | ₹1.75K Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 24 Apr 2026 | Buy Back | BUYBACK |
| 21 Jul 2025 | Dividend - Rs 5.80 Per Share | DIVIDEND |
| 17 Sept 2024 | Dividend - Rs 5.50 Per Share | DIVIDEND |
| 17 Sept 2024 | Annual General Meeting | AGM |
| 05 Sept 2023 | Annual General Meeting/Dividend - Rs 4 Per Share | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for WINDLAS
View AllNEWS
positive
Business Standard - Markets 50d ago
Windlas Biotech consolidated net profit declines 1.78% in the March 2026 quarter
Sales rise 17.66% to Rs 238.50 crore
WINDLASHealthcare
positive
ET Markets - Stocks 86d ago
Share buybacks this month: Wipro, Aurobindo Pharma, 2 other stocks to watch out for
Four companies—Wipro, Cyient, Windlas Biotech, and Aurobindo Pharma—are set to announce or act on share buybacks this month, with Aurobindo’s record date due soon. Buybacks involve companies repurchasing shares to boost value, use surplus cash, or strengthen ownership. Meanwhile, new rules under the Finance Bill 2026 impose a 12% surcharge on buyback-related capital gains for promoters, while other investors remain taxed as per existing norms.
APTUSAUROPHARMACAPITALSFBCIFLCPCAPCYIENTINDOSTARLTFVALUEWINDLASWIPROFinancial ServicesHealthcare